Patents by Inventor Jefferson Foote
Jefferson Foote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160082105Abstract: Compositions and methods are provided in embodiments directed to maintaining a desired concentration range of one or more drugs in a subject, and in particular embodiments to maintaining a desired drug concentration in a body compartment in a subject, based on the surprising discovery that antibodies persist in solution in body compartments such that antibody-antigen equilibrium principles can counteract drug clearance mechanisms. One or more antibodies are selected that have a dissociation constant KD that is similar to the desired drug concentration, wherein KD is independent of the affinity of the drug for a specific drug target (receptor) in the subject.Type: ApplicationFiled: September 24, 2015Publication date: March 24, 2016Inventors: Jefferson FOOTE, Carol E. O'HEAR
-
Patent number: 9173958Abstract: Compositions and methods are provided in embodiments directed to maintaining a desired concentration range of one or more drugs in a subject, and in particular embodiments to maintaining a desired drug concentration in a body compartment in a subject, based on the surprising discovery that antibodies persist in solution in body compartments such that antibody-antigen equilibrium principles can counteract drug clearance mechanisms. One or more antibodies are selected that have a dissociation constant KD that is similar to the desired drug concentration, wherein KD is independent of the affinity of the drug for a specific drug target (receptor) in the subject.Type: GrantFiled: September 13, 2005Date of Patent: November 3, 2015Assignee: Arrowsmith Technologies CorporationInventors: Jefferson Foote, Carol E. O'Hear
-
Publication number: 20110137014Abstract: Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences.Type: ApplicationFiled: March 29, 2010Publication date: June 9, 2011Applicant: Arrowsmith Technology Licensing, LLCInventor: Jefferson Foote
-
Patent number: 7732578Abstract: Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences.Type: GrantFiled: February 8, 2005Date of Patent: June 8, 2010Assignee: Arrowsmith Technology Licensing LLCInventor: Jefferson Foote
-
Patent number: 7709226Abstract: Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences.Type: GrantFiled: May 10, 2006Date of Patent: May 4, 2010Assignee: Arrowsmith Technology Licensing LLCInventor: Jefferson Foote
-
Publication number: 20070003547Abstract: Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences.Type: ApplicationFiled: May 10, 2006Publication date: January 4, 2007Applicant: Arrowsmith Technologies LLPInventor: Jefferson Foote
-
Publication number: 20060062778Abstract: Compositions and methods are provided in embodiments directed to maintaining a desired concentration range of one or more drugs in a subject, and in particular embodiments to maintaining a desired drug concentration in a body compartment in a subject, based on the surprising discovery that antibodies persist in solution in body compartments such that antibody-antigen equilibrium principles can counteract drug clearance mechanisms. One or more antibodies are selected that have a dissociation constant KD that is similar to the desired drug concentration, wherein KD is independent of the affinity of the drug for a specific drug target (receptor) in the subject.Type: ApplicationFiled: September 13, 2005Publication date: March 23, 2006Inventors: Jefferson Foote, Carol O'Hear
-
Publication number: 20050261480Abstract: Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences.Type: ApplicationFiled: February 8, 2005Publication date: November 24, 2005Inventor: Jefferson Foote
-
Patent number: 6881557Abstract: Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences.Type: GrantFiled: July 12, 2002Date of Patent: April 19, 2005Assignee: Arrowsmith Technologies LLPInventor: Jefferson Foote
-
Publication number: 20030039649Abstract: Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences.Type: ApplicationFiled: July 12, 2002Publication date: February 27, 2003Inventor: Jefferson Foote